Lumida
/GERN
⌘K
Geron Corp

Geron Corp

GERN
$1.44USD↑+1.41%+0.02 today

MARKET CAP

923.8M

P/E (TTM)

—

FWD P/E

46.3x

DAY RANGE

$1 – $1

52W RANGE

$1
$2

AI Summary

Stalk
StalkMedium

GERN is in a Stage 2 advance with a bullish medium-term bias confirmed by a Momentum Breakout and higher highs/lows. Yet price is now extreme overbought and extended well above the rising EMAs, so execution is deferred until shallow pullbacks into the 9/20/50 EMA support zone.

  • ↑Q1 net revenue $51.8M (31% YoY), on track for $220–240M guidance
  • ↑$341M cash position supports R&D spend and market expansion
  • ↓Projected 2026 operating expenses of $230–240M accelerate cash burn
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Geron Corporation (NASDAQ: GERN) is a biopharmaceutical company focusing on developing innovative therapies for blood cancers, particularly its lead product, Rytello (metelstat), which targets lower-risk myelodysplastic syndromes (MDS). Positioned as a rising player in the hematology sector, Geron aims to expand its market presence in both the U.S. and Europe, addressing significant unmet medical needs while navigating complex market dynamics challenged by competitive forces and regulatory hurdles.

Bull says

  • ↑Q1 net revenue $51.8M (31% YoY), on track for $220–240M guidance
  • ↑$341M cash position supports R&D spend and market expansion
  • ↑Prescribing accounts up 15%, boosting community physician uptake
  • ↑Analysts’ median target $4.00 implies 167% upside vs $1.50
  • ↑High institutional ownership and value-factor exposure suggest hidden upside
  • ↑Strong QS score and positive oil sensitivity may amplify gains

Bear says

  • ↓Projected 2026 operating expenses of $230–240M accelerate cash burn
  • ↓Cash down from $401M in 2025 to $341M in Q1 2026 limits runway
  • ↓3% QoQ demand decline evidences commercial execution risks
  • ↓European launch faces complex regulations and pricing hurdles
  • ↓Negative earnings yield and profitability factors signal weak returns
  • ↓High volatility and small-size factor headwinds may exacerbate share swings

Investment themes with GERN

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-10-2026bullish

Transcript signals

Bull points

  • RightOwl's first quarter net revenue was $51.8 million, an increase of 31% year-over-year and 8% quarter-over-quarter, placing us on track to achieve our 2026 net revenue guidance of $220 million to $240 million.
  • Growing Ritello demand in the U.S. market remains our priority, and we know from patients at ECTD there is an unmet need for low-risk MDS treatment options in Europe and an interest in Ritello to help address that need.
  • We expect to communicate our commercial plans for Europe before the end of the year, once we have clarity on pricing and market opportunities.

Bear points

  • Gross-to-net deductions increased to 21% for the three months ended March 31, 2026, compared to 13% for the same period last year.
  • The reduction is primarily related to decreased headcount as a result of the workforce reduction in December 2025.
Read full transcript analysis ›